What is it about?
In this paper we show that CLL cells can internalize LPL from plasma, independent of their IgHV mutational status. Moreover, we provide a protocol for the efficient flow cytometric evaluation of LPL protein in CLL, and evidence the need of further validating this marker in prognostic.
Featured Image
Why is it important?
It had long been known that LPL cells with an unmutated IgHV profile express LPL mRNA, and mutated IgHV patients do not. These differences in their transcriptional profile proved useful for patient stratification into risk groups. However, some molecular biology analyses are not routinely performed worldwide in the hematological practice. This is why developing a method for the evaluation of LPL protein by flow cytometry -widely used in hematological laboratory routine- became essential. Until now, efforts for developing LPL protein as a prognostic marker in CLL were unsuccessful. In the paper we provide a possible explanation for these previous failures, describing the ability of CLL cells to internalize LPL from plasma regardless of LPL transcriptional status. Furthermore, the development of the prococol for LPL evaluation in flow cytometry reopens the hope of using it for predicting disease outcome.
Perspectives
This article will surely help understanding the role of LPL in CLL, as it provides a key piece for the understanding of the metabolic role of LPL in leukemic B-cells. I hope in the future other groups would validate LPL as a prognostic marker in larger patient cohorts.
Dr Daniel Prieto
Instituto de Investigaciones Biologicas Clemente Estable
Read the Original
This page is a summary of: LPL protein in Chronic Lymphocytic Leukaemia have different origins in Mutated and Unmutated patients. Advances for a new prognostic marker in CLL, British Journal of Haematology, June 2018, Wiley,
DOI: 10.1111/bjh.15427.
You can read the full text:
Contributors
The following have contributed to this page
